Develops NGS-based products for cancer diagnosis.
Dec 2025Revenue $77.2M/yrExpenses $85.0M/yr
No trendCash runway over 10 years from Dec 2025
Figures by year
When will Burning Rock Biotech be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $77.2M and expenses $85.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $77.2M | $85.0M | −$7.84M |
| Dec 2024 | $70.7M | $120M | −$49.0M |
| Dec 2023 | $75.7M | $170M | −$94.3M |
| Dec 2022 | $81.7M | $224M | −$142M |
| Dec 2021 | $79.7M | $205M | −$125M |
| Dec 2020 | $65.9M | $129M | −$63.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.